TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00667329
Drug: 2CdA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/m\^2 subcutaneous injection three times daily x 7 days.
Study: NCT00667329
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg/m\^2 PO twice daily x 7 days.
Study: NCT04622917
Drug: MethylPREDNISolone 40 Mg/mL Injectable Suspension
Normalized name: methylPREDNISolone 40 mg/mL injectable suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: intramuscular injection
Study: NCT00047710
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 650mg/m\^2 taken by mouth twice a day 15-52 during the radiotherapy.
Study: NCT04622917
Drug: NaCl 9 MG/ML Injectable Solution
Normalized name: NaCl 9 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection
Study: NCT01053156
Drug: minocycline hydrochloride
Normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline hydrochloride dosed orally once a day for 3 months.
Study: NCT01053156
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given daily for 3 months.
Study: NCT02121795
Drug: FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200/300 mg FDC tablets administered orally once daily
Study: NCT02121795
Drug: Allowed third antiretroviral agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: An allowed third antiretroviral agent of the participant's pre-existing regimen may include one of the following: ritonavir-boosted atazanavir (ATV/r), ritonavir-boosted lopinavir (LPV/r), ritonavir-boosted darunavir (DRV/r), efavirenz (EFV; Sustiva®), rilpivirine (RPV; Edurant®), nevirapine (NVP;Viramune®), raltegravir (RAL; Isentress®), dolutegravir (DTG;Tivicay®), and maraviroc (MVC; Selzentry®).
Study: NCT02121795
Drug: FTC/TDF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally once daily
Study: NCT02121795
Drug: F/TAF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally once daily
Study: NCT02752815
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03076359
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-line ART will consist of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI)- TDF + 3TC (or FTC) + EFV as a fixed-dose combination to be taken twice a day for the rest of the patient's life), clinic-based counseling, and community searches if lost to follow up.
Study: NCT01179607
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03645642
Drug: Diuretics
Normalized name: DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics will be continued with an maximum dose of furosemide (160mg) and Aldactone 400 mg.
Study: NCT00395850
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram at 0, 250, 375, or 500 mg/day for 12 weeks
Study: NCT04605289
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be administered by means of a syringe with a bent, blunt-end needle. The needle will be carefully inserted into the periodontal pocket and the gel will be applied in the test sites in a gentle probing manner, attempting to fill the full extent of the pocket. The gel will be applied up to the gingival margin and the excess gel will be removed with sterile gauze.~Periodontal dressing will be applied after the delivery of the drug, and they will be also asked not to eat for thirty minutes.~After placement of the gel in situ, patients will be instructed to follow strict oral hygiene protocol and not chew hard or sticky foods at the gel placement sites for rest of the week.
Study: NCT00506298
Drug: bezafibrate + diflunisal
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate + diflunisal
Study: NCT03178292
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Tablet daily for 5 days
Study: NCT02990403
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00320060
Drug: Pyridorin (pyridoxamine dihydrochloride)
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00917826
Drug: Arginine Butyrate
Normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg/kg/day administered IV over 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
Study: NCT01950299
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 0.67 ml injections twice daily
Study: NCT02291588
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: contains no active drug
Study: NCT02941315
Drug: etiologic treatment,anti-myocardial remodeling
Approvals — FDA: no, EMA: no, PMDA: no
Description: When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), participants were treated with drugs including etiologic treatment,anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.
Study: NCT02941315
Drug: anti-myocardial remodeling
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant without companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.
Study: NCT02941315
Drug: anti-myocardial remodeling,anti-acute heart failure
Approvals — FDA: no, EMA: no, PMDA: no
Description: When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling and anti- acute failure according to guidelines.
Study: NCT02941315
Drug: Etiological, anti-remodeling and symptom treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), in participants were companioned with acute heart failure, the participant should be treated with drugs including etiologic treatment,anti-myocardial remodeling and anti-acute heart failure according to guidelines for treatment of cardiomyopathy.
Study: NCT02731378
Drug: Aggressive iron dextran supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron dextran 100 mg, BIW, through 90 minutes of IV infusion, for the first consecutive 5 weeks
Study: NCT02731378
Drug: Sustained iron dextran supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron dextran 200 mg, Q3W, through 90 minutes of IV infusion and a maximum of 5 doses
Study: NCT04512963
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A substance that has no therapeutic effect, used as a control in testing Progerinin
Study: NCT02338713
Drug: Calcichew D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 500 mg and vitamin D3 1000 IU chewable tablets
Study: NCT02092454
Drug: Benzocaine
Normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical otic solution
Study: NCT02092454
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical otic solution
Study: NCT04574089
Drug: Experimental: Baofukang Suppository 7 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental: Baofukang Suppository 7 days
Study: NCT04574089
Drug: Experimental: Baofukang Suppository 14 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental: Baofukang Suppository 14 days
Study: NCT03280407
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Radio-chemotherapy with 50.4 Gy in 28 fractions to tumor and regional lymph nodes concomitantly with capecitabine 825 mg/m2 b.i.d
Study: NCT03280407
Drug: FOLFOX regimen (oxaliplatin/leucovorin/5FU)
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six cycles: Oxaliplatin 85 mg/m2 day 1, leucovorin 400 mg/m2 day 1, 5FU 400 mg/m2 bolus day 1 and 5FU 2400 mg/ m2 over 46-48 hours day 1-3, repeated every two weeks.
Study: NCT03280407
Drug: CAPOX (oxaliplatin/capecitabine)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Four cycles: Oxaliplatin 130 mg/m2 day 1 and capecitabine 1000 mg/m2 b.i.d. days 1-14, repeated every 3 weeks.
Study: NCT02619617
Drug: SOM230
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study evaluated SOM230 vs Placebo
Study: NCT02619617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study evaluated SOM230 vs Placebo
Study: NCT01967147
Drug: Propylene Glycol, 0.6% eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially available eye drops used during Treatment Phase
Study: NCT01967147
Drug: Preservative-free 0.9% Saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially available solution used as Run-in (1 drop in each eye 4 times a day for 15 days) and during Treatment Phase
Study: NCT01774877
Drug: Xinfeng capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinfeng capsule:Three each time, 3 times a day, Oral,for 3 months; placebo(for leflunomide):10mg each time, 1 time a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and NSAIDs that they were receiving prior to study entry
Study: NCT02644395
Drug: Chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug
Study: NCT02862587
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin：60mg/m2，Gemcitabine：1g/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
Study: NCT03404856
Drug: ORL-1G - D-galactose
Normalized name: D(+)-Galactose
DrugBank: Galactose (DB11735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ORL-1G - D-galactose
Study: NCT03110328
Drug: MK3475
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-PD1 immunotherapy
Study: NCT02603172
Drug: GSK3039294
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3039294 will be provided as white, opaque capsules. A single capsule or multiple capsules (20 mg to 200 mg), depending on the dosage required, will be taken orally with water.
Study: NCT01936363
Drug: SAR245409 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching SAR245409 administered once daily in morning until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
Study: NCT01936363
Drug: SAR245409
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR245409 administered as oral capsule at a dose of 70 milligram (mg) once daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
Study: NCT00275171
Drug: recombinant human TSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg rhTSH administered intramuscularly
Study: NCT01676493
Drug: Codeine
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01373697
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Apply the gel at the site of pain or injury, massaging gently to promote penetration of 8 in 8 hours for 5 days. Leave the gel on the premises at least 4 hours before removal
Study: NCT02016443
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Placebo (Group P) will receive a placebo per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
Study: NCT02762084
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03276598
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment for four weeks. Dose: 1 tablet per day.
Study: NCT00053885
Drug: PTK787/ZK 222584
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00099086
Drug: GnRh analog
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: A GnRH analog (goserelin acetate, leuprolide acetate) will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)~Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)
Study: NCT01043458
Drug: ABT-126
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-126 Low Dose \& ABT-126 High Dose
Study: NCT01043458
Drug: Placebo for ABT-126
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo for Arms 1 \& 2
Study: NCT01963702
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01139996
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo oral tablet and the overlay patch only and in 12 hours they will receive a second and final tablet
Study: NCT01753882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agent + training vs Placebo + training
Study: NCT01566604
Drug: NVA237
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivered via a single dose dry powder inhaler
Study: NCT01566604
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivered via a single dose dry powder inhaler
Study: NCT00676403
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control (capsule), once a day, 1- 3 hours before bedtime for 6 weeks
Study: NCT02634073
Drug: Sorbitol
Normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It is a clear, colorless, odourless solution. It will be available in 3 dosage levels viz;. 3.2 g (low dose), 10.2 g (medium dose) and 13.4 g (high dose) sorbitol total dose.
Study: NCT02898454
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Study: NCT00972959
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg, iv, at a 15 min infusion, Day 1 of every cycle for up to 8 cycles, and then every 28 days for the next 18 months
Study: NCT00529711
Drug: Hypertonic lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution given parenterally as follows:~Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours.
Study: NCT00529711
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution given parenterally as follows:~Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours.
Study: NCT04302402
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar looking placebo
Study: NCT02432339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a sugar pill - 500 mgs twice a day for 7 1/2 days - in the same capsule form as the MMF
Study: NCT03048877
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Tablet
Study: NCT02718911
Drug: LY3022855
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT00467428
Drug: NS2359
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00467428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05237726
Drug: Unfractionated heparin 5000 U q8 hours
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
Study: NCT01820247
Drug: enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01820247
Drug: Tripterygium glycosides
Normalized name: anthraquinone glycoside
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03589807
Drug: AS03
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03 oil-in-water emulsion adjuvant.
Study: NCT00672568
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution, single dose, injection
Study: NCT03009864
Drug: Tangshen Prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: The prescription contains granules of five Chinese herbal medicines, every bag weighs 4.87g, take it one bag each time, two times a day.
Study: NCT03009864
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with placebo corresponding to each dose of Tangshen Prescription , every bag weighs 4.87g, take it one bag each time, two times a day.
Study: NCT01906788
Drug: Artemether Lumefantrine
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02732808
Drug: Ovulation stimulation
Normalized name: Ovulation stimulants, synthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double stimulation in 2 phases:~Phase I: Clomiphene citrate (Ovumid®) 25 mg/day with co-treatment of Letrozole (Letrofem®) 2.5 mg/day are given from cycle day 3 onwards. Letrozole (Letrofem®) 2.5 mg/day are given from cycle day 3 onwards. human menopausal gonadotrophin (HMG) Menopur®150 IU every other day beginning on cycle day 6. triptorelin (Decapeptyl®) 100 μg follows by ibuprofen 600 mg.~Phase 2:A total of 225 IU HMG(Decapeptyl®) and letrozole (Letrofem®) 2.5 mg is administered daily .Daily administration of medroxyprogesterone acetate (Progestrone®)10 mg. . the final stage of oocyte maturation is induced again with triptorelin (Decapeptyl®)100 μg by injection.
Study: NCT01435759
Drug: Antidepressant + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, once daily for 8 weeks
Study: NCT00757393
Drug: Vitamin D + Calcium + Exercise program + Humatrope
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in this arm will receive the same as those in arm 1 as well as Humatrope by subcutaneous infection 7 days a week at a dose of 0.05 mg.kg/day.
Study: NCT01691690
Drug: Acetaminophen (paracetamol)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen IV (15 mg/kg).
Study: NCT01691690
Drug: Normal Saline Flush
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo will be infused intraoperatively.
Study: NCT01569126
Drug: LY110140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as capsules
Study: NCT01569126
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as capsules in the placebo arm and to maintain the blind in the 20 mg LY110140 (MD) arm
Study: NCT04062760
Drug: Standard diuretic therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in this arm will be randomized to receiving oral furosemide in 2 daily divided doses at twice the intravenous dose administered during the past 24 hours. Unless serum potassium value is higher than 5 mmol/L, oral spironolactone or potassium canrenoate will be added; dose will be established based on serum creatinine value.
Study: NCT00436072
Drug: ZD6474
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally on a daily basis
Study: NCT01108926
Drug: Atripla®
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will be administered Atripla® (tenofovir 245 mg plus emtricitabine 200 mg plus efavirenz 600 mg), one tablet orally once daily for 14 days
Study: NCT02117453
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 20 mg/day
Study: NCT02117453
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02392520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous albumin administration, paracentesis of ascitic fluid, correction of electrolyte imbalance and intravascular volume
Study: NCT00946023
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -6 and -5: 14.5 mg/kg IV daily; Days 3 and 4: 50 mg/kg IV daily
Study: NCT00145769
Drug: Short Course Adjuvent Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post operative adjuvant chemotherapy: 5FU (425mg/m2) preceded by Folinic acid (20mg/m2) delivered over 5 days for 6 monthly cycles
Study: NCT00145769
Drug: Long Course Adjuvant Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post operative adjuvant 5FU (425mg/m2) preceded by folinic acid (20mg/m2) delivered over 5 days for 4 monthly cycles
Study: NCT00024141
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02710708
Drug: EE20/DRSP (YAZ, BAY86-5300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: YAZ (DRSP 3 mg/EE 20 µg), oral route, 6 cycles of 28 days per cycle, each cycle comprising 24 days of active tablets followed by 4 days of placebo tablets
Study: NCT02324010
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive drug (Placebo)
Study: NCT00667056
Drug: placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical
Study: NCT04410510
Drug: P2Et (Caesalpinia spinosa extract)
Normalized name: Caesalpinia spinosa whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: P2Et active extract capsule equivalent to 250mg of P2Et every 12 hours for 14 days + Standard Care
Study: NCT00432861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT00697021
Drug: Aspirin 100mg and Plavix 75mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responders to standard dual antiplatelet therapy as observed by TEG analysis will continue standard doses of Aspirin and Plavix
Study: NCT02607670
Drug: TAT4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02607670
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no